These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21671833)

  • 1. Experiences and needs for work participation in employees with rheumatoid arthritis treated with anti-tumour necrosis factor therapy.
    Van der Meer M; Hoving JL; Vermeulen MI; Herenius MM; Tak PP; Sluiter JK; Frings-Dresen MH
    Disabil Rehabil; 2011; 33(25-26):2587-95. PubMed ID: 21671833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Work ability of Dutch employees with rheumatoid arthritis.
    de Croon EM; Sluiter JK; Nijssen TF; Kammeijer M; Dijkmans BA; Lankhorst GJ; Frings-Dresen MH
    Scand J Rheumatol; 2005; 34(4):277-83. PubMed ID: 16195160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Work ability: a new outcome measure in rheumatoid arthritis?
    Raterman HG; Hoving JL; Nurmohamed MT; Herenius MM; Sluiter JK; Lems WF; Tak PP; Dijkmans BA; Twisk J; Frings-Dresen MH; Voskuyl AE
    Scand J Rheumatol; 2010 Mar; 39(2):127-31. PubMed ID: 20059369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of decoy receptor- and antibody-mediated tumour necrosis factor blockage on FoxP3 expression in responsive arthritis patients.
    Ryder LR; Ryder LP; Bartels EM; Woetmann A; Madsen HO; Ødum N; Danneskiold-Samsøe B; Ribel-Madsen S; Bliddal H
    APMIS; 2013 Apr; 121(4):337-47. PubMed ID: 23031059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
    Wolfe F; Michaud K
    J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK; Petersson IF; Geborek P
    Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment.
    Bassetti S; Wasmer S; Hasler P; Vogt T; Nogarth D; Frei R; Widmer AF
    J Rheumatol; 2005 Nov; 32(11):2125-9. PubMed ID: 16265689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptations made by rheumatoid arthritis patients to continue working: a pilot study of workplace challenges and successful adaptations.
    Mancuso CA; Paget SA; Charlson ME
    Arthritis Care Res; 2000 Apr; 13(2):89-99. PubMed ID: 14635282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability.
    Wolfe F; Allaire S; Michaud K
    J Rheumatol; 2007 Nov; 34(11):2211-7. PubMed ID: 17787043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
    Straub RH; Härle P; Atzeni F; Weidler C; Cutolo M; Sarzi-Puttini P
    J Rheumatol; 2005 Jul; 32(7):1253-8. PubMed ID: 15996060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
    Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
    Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis.
    Mayer Y; Balbir-Gurman A; Machtei EE
    J Periodontol; 2009 Sep; 80(9):1414-20. PubMed ID: 19722791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression.
    Netea MG; Radstake T; Joosten LA; van der Meer JW; Barrera P; Kullberg BJ
    Arthritis Rheum; 2003 Jul; 48(7):1853-7. PubMed ID: 12847679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.